Acknowledgements
NEUROMUSCULAR DISEASES
We thank all the RAP-ALS investigators group (see supplementary material). We thank the participants in the RAP-ALS trial and their families and caregivers, without whom this trial would have not been possible; Dr. Graziella Filippini, Dr. Ettore Beghi, Dr. Lawrence Korngut and Dr. Paola Minghetti, members of the data and safety monitoring board; Neurobiobank of Modena; Telethon Genetic BioBank (GTB12001D) and the Eurobiobank network; European Reference Network for Neuromuscular Diseases (ERN EURO-NMD); CRO High Research- Evidenze Group.